The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy

Pediatric Blood and Cancer

Volumn 60, Issue 3, 2013, Pages 474-478

  Abujamra, Ana Lucia ^a,b   Escosteguy, Juliana Ribas ^c   Dall'Igna, Celso ^b   Manica, Denise ^b   Cigana, Luciana Facchini ^b   Coradini, Patrícia ^b   Brunetto, André ^b   Gregianin, Lauro José ^a,b  

^a Children's Cancer Institute   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c HOSPITAL MÃE DE DEUS   (Brazil)

Author keywords

Cisplatin; High frequency audiometry; Ototoxicity

Indexed keywords

CISPLATIN;

ADOLESCENT; ADULT; ARTICLE; ASYMPTOMATIC HEARING LOSS; AUDIOMETRY; BRAZIL; CASE REPORT; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DISTORTION PRODUCT OTOACOUSTIC EMISSION; DRUG SAFETY; FEMALE; HEARING IMPAIRMENT; HUMAN; INFORMED CONSENT; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; AUDIOMETRY; CHILD; CHILD, PRESCHOOL; CISPLATIN; FEMALE; HEARING LOSS, SENSORINEURAL; HUMANS; MALE; NEOPLASMS; YOUNG ADULT;

EID: 84872484515     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24236     Document Type: Article

References (45)

1. Rybak LP, Whitworth CA, Mukherjea D, et al. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2007; 226: 157-167.
2. Rybak LP, Mukherjea D, Jajoo S. Cisplatin ototoxicity and protection: Clinical and experimental studies. Tohoku J Exp Med 2009; 219: 177-186.
3. Lanvers-Kaminsky C, Krefeldt B, Dinnensen AC, et al. Continuous or repeated prolonged cisplatin infusions in children: A prospective study on ototoxicity, platinum concentrations and standard serum parameters. Pediatr Blood Cancer 2006; 47: 183-193.
4. Hellberg V, Walin SE, Hernlund E, et al. Cisplatin and oxaliplatin toxicity: Importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst 2009; 101: 37-47.
5. Fausti SA, Wilmington DJ, Helt PV, et al. Hearing health and care: The need for improved hearing loss prevention and hearing conservation practices. J Rehabil Res Dev 2005; 42: 45-62.
6. Jacob LCB, Aguiar FP, Tomiasi AA, et al. Auditory monitoring in ototoxicity. Braz J Otorhinolaryngol 2006; 72: 836-844.
7. Gordon JS, Phillips DS, Helt WJ, et al. Evaluation of insert earphones for high-frequency bedside ototoxicity monitoring. J Rehabil Res Dev 2005; 42: 353-362.
8. Knight KRG, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005; 23: 8588-8596.
9. Knight KR, Kraemer DF, Winter C, et al. Early changes in auditory function as a result of platinum chemotherapy: Use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 2007; 25: 1190-1195.
10. Skinner R. Best practice in assessing ototoxicity in children with cancer. Eur J Cancer 2004; 40: 2352-2354.
11. Skinner R. Preventing platinum-induced ototoxicity in children-Is there a potential role for sodium thiosulfate? Pediatr Blood Cancer 2006; 47: 120-122.
12. Pasic TR, Dobie RA. Cis-platinun ototoxicity in children. Laryngoscope 1991; 101: 985-991.
13. Stelmachowicz PG, Pittman AL, Hoover BM, et al. The importance of high-frequency audibility in the speech and language development of children with hearing loss. Arch Otolaryngol Head Neck Surg 2004; 130: 556-562.
14. Bellman SC. Monitoring chemotherapy-induced hearing loss in children. Eur J Cancer 1996; 32A: 1185-1188.
15. Konrad-Martin D, Helt WJ, Reavis WM, et al. Ototoxicity: Early detection and monitoring. ASHA Leader Am Speech Lang Hearing Assoc 2005; 10: 11-14.
16. Coradini PP, Cigana L, Selistre SG, et al. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol 2007; 29: 355-366.
17. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: The influence of age and the cumulative dose. Eur J Cancer 2004; 40: 2445-2451.
18. Previati M, Lanzoni I, Astolfi L, et al. Cisplatin cytotoxicity in organ of Corti-derived immortalized cells. J Cell Biochem 2007; 101: 1185-1197.
19. Bosch ME, Sanchez AJR, Rojas FS, et al. Analytical methodologies for the determination of cisplatin. J Pharm Biomed Anal 2008; 47: 451-459.
20. Arora S, Thakur JS, Azad RK, et al. Cisplatin-based chemotherapy: Add high-frequency audiometry in the regimen. Indian J Cancer 2009; 46: 311-317.
21. Einarsson EJ, Petersen H, Wiebe T, et al. Long term hearing degeneration after platinum-based chemotherapy in childhood. Int J Audiol 2010; 49: 765-771.
22. Einarsson EJ, Petersen H, Wiebe T, et al. Severe difficulties with word recognition in noise after platinum chemotherapy in childhood, and improvements with open-fitting hearing-aids. Int J Audiol 2011; 50: 642-651.
23. Hall JW III, Chandler D. Timpanometria na audiologia clínica (cap.20). In: Katz J, editor. Tratado de audiologia Clínica. Manole: São Paulo. 1999. pp. 281-297.
24. Russo ICP, Santos TMM. Interpretação dos resultados da avaliação audiológica (Ch. 9). In: Russo ICP, Santos TMM, editors. A Prática da audiologia Clínica. Cortez: São Paulo. 1993. pp. 191-212.
25. Pedalini MEB, Sanchez TG, D'Antonio A, et al. Média dos limiares tonais na audiometria de alta freqüência em indivíduos normais de 4 a 60 anos. Pro Fono 2000; 12: 17-20.
26. Sahyeb DR, Filho OAC, Alvarenga KF. Audiometria de alta freqüência: Estudo com indivíduos audiologicamente normais. Rev Bras Otorrinolaringol 2003; 69: 93-99.
27. Carvallo RMM, Koga MC, Ishida IM. Limiares auditivos para altas freqüências em adultos sem queixa auditiva. ACTA ORL/Técnicas em Otorrinolaringologia 2007; 25: 62-66.
28. Al-Khatib T, Cohen N, Carret AS, et al. Cisplatinum ototoxicity in children, long-term follow up. Int J Pediatr Otorhinolaryngol 2010; 74: 913-919.
29. Park KR. The utility of reflex thresholds and other conventional audiologic tests for monitoring cisplatin ototoxicity in the pediatric population. Ear Hear 1996; 17: 107-115.
30. Garcia AP, Iório MCM, Petrilli AS. Monitoramento da audição de pacientes expostos à cisplatina. Rev Bras Otorrinolaringol 2003; 69: 215-221.
31. Dishtchekenian A, Iório MCM, Petrilli AS, et al. Audiological follow up in patients with osteossarcoma who had chemotherapy using cisplatin. Braz J Otorhinolaryngol 2000; 66: 580-590.
32. Sá LCB, Lima MAMT, Tomita S, et al. Avaliação dos limiares de audibilidade das altas freqüências em indivíduos entre 18 e 29 sem queixas otológicas. Rev Bras Otorrinolaringol 2007; 73: 215-225.
33. Dhooge I, Dhooge C, Geukens S, et al. Distortion product otoacoustic emissions: Na objective technique for the screening of hearing loss in children treated with platin derivates. Int J Audiol 2006; 45: 337-343.
34. Almeida EOC, Umeoka WG, Viera RC, et al. High frequency audiometric study in cancer-cured patients treated with cisplatin. Braz J Otorhinolaryngol 2008; 74: 382-390.
35. Ress BD, Sridhar KS, Balkany TJ, et al. Effects of cis-platinum chemotherapy on otoacoustic emissions: the development of an objective screening protocol. Otolaryngol Head Neck Surg 1999; 121: 693-701.
36. Rademaker-Lakhai JM, Crul M, Zuur L, et al. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol 2006; 26: 918-924.
37. Frank T. High-frequency (8 to 16kHz) reference thresholds and intrasubject threshold variability relative to ototoxicity criteria using a sennheiser HAD 200 earphone. Ear Hear 2001; 22: 161-168.
38. Musial-Bright L, Fengler R, Henze G, et al. Carboplatin and ototoxicity: Hearing loss rates among survivors of childhood medulloblastoma. Childs Nerv Syst 2011; 27: 407-413.
39. Sivaprakasam P, Gupta AA, Greenberg ML, et al. Survival and long-term outcomes in children with hepatoblastoma treated with continuous infusion of cisplatin and doxorubicin. J Pediatr Hematol Oncol 2011; 33: e226-e230.
40. Chen SH, Liang DC, Lin HC. Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients. J Pediatr Hematol Oncol 2005; 27: 651-653.
41. Grewal S, Merchant T, Reymond R, et al. Auditory late effects of childhood cancer therapy: A report from the children's oncology group. Pediatrics 2010; 125: e938-e950.
42. Hitchcock YJ, Tward JD, Szabo A. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 2009; 73: 779-788.
43. Stavroulaki P, Apostolopoulos N, Segas J, et al. Evoked otoacoustic emissions-An approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol 2001; 59: 47-57.
44. Erdem T, Bayindir T, Filiz A, et al. The effect of resveratrol on the prevention of cisplatin ototoxicity. Eur Arch Otorhinolaryngol 2011; 269 [Epub ahead of print].
45. Yumusakhuylu AC, Yazici M, Sari M, et al. Protective role of resveratrol against cisplatin induced ototoxicity in guinea pigs. Int J Pediatr Otorhinolaryngol 2012; 76: 404-408.